Ahmad Masri
MasriAhmadMD
These are the #HCM sessions and abstracts (original research) I am looking forward to @ #ACC21 - add the ones I missed First - an important analysis from the EXPLORER-HCM
Read more
An interesting contrast of the @US_FDA label for tafamidis (in ATTR-CM) vs daratumumab (in AL). NYHA class IV were excluded in ATTRACT and NYHA class IIIb and IV excluded in
Read more
Thread/ This was a great day for #HCM patients. The results of EXPLORER-HCM were presented #ESC2020 and published ( https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31792-X/fulltext ). This timeline shows some of the major
Read more
In this letter we summarize our experience prescribing #tafamidis at @OHSUSOM @OHSUCardio in @JAMACardioGoal:summarize the out of pocket cost of tafamidis to patients and raise awareness about utilizing available resources
Read more